Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 February 2023 | Story Kekeletso Takang | Photo Supplied
Michelle De Lange
UFS School of Accountancy Lecturer, Michelle de Lange, aced the recent Chartered Global Management Accountants Board exam, obtaining second position.

Michelle de Lange, accredited Accounting Lecturer in the School of Accountancy at the University of the Free State (UFS), finished second in the world at the recent Chartered Global Management Accountant (CGMA) Board Examination. With only one point between De Lange and the first candidate, she aced the challenging exam.    

Having obtained fourth position in the world for the 2019 CIMA Gateway exam, De Lange was determined to outdo herself.

The Chartered Institute of Management Accountants (CIMA) is the world’s largest global professional management accounting body to offer training and qualification in management accountancy. As designation holders, members get to showcase their skills and experience to a global audience, while upholding professionalism and promoting continuous learning. 

De Lange, who holds another professional accreditation from the South African Institute of Chartered Accountants (SAICA), coordinates the BCom Honours in Management Accounting programme, which is CIMA-aligned for postgraduate students. For De Lange, the greatest reward is the realisation of the impact she is making on her students through strategic vision.  

Having worked in the private sector and later joining the UFS as an Assistant Director at Finance back in 2016, De Lange believed that something was missing; that there was more to give. In 2018 she moved to the School of Accountancy, taking on her new role as Lecturer. “I wanted to make a difference and be significant. This motivated my move to lecturing,” she says. 

Her passion for teaching extends beyond the lecture hall. De Lange pays it forward by supporting students through a hands-on approach and ensuring that assessments are CIMA-aligned. 

The School of Accountancy in the Faculty of Economic and Management Sciences is proud of De Lange and her achievements. 

Becoming a CGMA requires discipline. De Lange is grateful for the support she received in preparation for the board exam, in particular from her husband Francois, who was “always understanding and encouraging”. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept